Welcome to our dedicated page for Mira Pharma news (Ticker: MIRA), a resource for investors and traders seeking the latest updates and insights on Mira Pharma stock.
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) generates a steady flow of news as a clinical-stage biopharmaceutical company advancing oral and topical therapies for neurologic, neuropsychiatric, metabolic, and pain-related disorders. Company press releases and Form 8-K filings highlight progress across its pipeline, including Ketamir-2 for neuropathic pain and CNS indications, MIRA-55 for chronic inflammatory and nociceptive pain, and SKNY-1 for obesity and nicotine addiction following the acquisition of SKNY Pharmaceuticals.
On this news page, readers can follow updates on clinical trial milestones for Ketamir-2, such as completion of the single ascending dose Phase 1 study, initiation of the multiple ascending dose phase, and plans for Phase 2a evaluation in chemotherapy-induced peripheral neuropathy. News items also cover preclinical data releases, including peer-reviewed publications and conference presentations describing Ketamir-2’s performance versus ketamine, gabapentin, and pregabalin in validated neuropathic pain models, as well as topical Ketamir-2 data showing effects comparable to injected morphine in acute and inflammatory pain models.
MIRA’s news flow further includes pipeline expansion and transaction announcements, such as the closing of the SKNY Pharmaceuticals acquisition and new preclinical results for MIRA-55 demonstrating oral pain normalization and inflammation reduction relative to morphine. Corporate and financing updates, including at-the-market equity offerings and Nasdaq listing compliance developments, are also reported through current reports and press releases.
Investors, clinicians, and researchers can use this page to monitor how MIRA’s programs evolve from preclinical studies into human trials, track regulatory milestones like FDA IND clearance, and review strategic decisions that shape the company’s multi-program portfolio in neuropathic pain, chronic inflammatory pain, obesity, addiction, PTSD, and related areas.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.